IP Verse

Regeneron Pharmaceuticals, Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Regeneron Pharmaceuticals, Inc.

Patent Number:
EP4058148
Title:
Dosing Regimen For Anti-Bcma Agents
Applicant:
AMGEN INC.
Opposition Date:
Aug 2, 2024
Patent Number:
EP3631454
Title:
Treatment Of Lag-3 Positive Tumors
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Opposition Date:
Jun 13, 2024
Patent Number:
EP3911354
Title:
Aav-Mediated Gene Therapy Restoring The Otoferlin Gene
Applicant:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Opposition Date:
Apr 16, 2024
Patent Number:
EP3666797
Title:
Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
Applicant:
AMGEN, INC
Opposition Date:
Feb 19, 2024
Patent Number:
EP3597216
Title:
Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof
Applicant:
E. R. SQUIBB & SONS, L.L.C.
Opposition Date:
May 23, 2023
Patent Number:
EP3476942
Title:
Long Germline Dh Genes And Long Hcdr3 Antibodies
Applicant:
TRIANNI, INC.
Opposition Date:
Oct 25, 2022
Patent Number:
EP3785536
Title:
Adam6 Knockin Mice
Applicant:
TRIANNI, INC.
Opposition Date:
Oct 25, 2022
Patent Number:
EP3241435
Title:
Animal Models And Therapeutic Molecules
Applicant:
KYMAB LIMITED
Opposition Date:
Feb 25, 2022
Patent Number:
EP3322731
Title:
Method Of Treating Cancer Using Immune Checkpoint Inhibitor
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Opposition Date:
Oct 7, 2021
Patent Number:
EP3036256
Title:
Modulation Of Tumor Immunity
Applicant:
MERCK SHARP & DOHME CORP.
Opposition Date:
Jul 27, 2021

Latest patents of Regeneron Pharmaceuticals, Inc. opposed by its competitors

Patent:
EP4011915
Grant Date:
Nov 15, 2023
Title:
Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist
Oppositions:
6
Patent:
EP2967015
Grant Date:
Aug 9, 2023
Title:
Transgenic Mice Expressing Chimeric Major Histocompatibility Complex (Mhc) Class Ii Molecules
Oppositions:
1
Patent:
EP3384049
Grant Date:
Aug 2, 2023
Title:
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf
Oppositions:
4
Patent:
EP2790681
Grant Date:
Jul 26, 2023
Title:
Polymer Protein Microparticles
Oppositions:
1
Patent:
EP3085780
Grant Date:
Jun 28, 2023
Title:
Producing Hybrid Antibodies Containing Human Variable Regions And Rodent Constant Regions
Oppositions:
1
Patent:
EP3085779
Grant Date:
May 31, 2023
Title:
Method Of Modifying Eukaryotic Cells
Oppositions:
1
Patent:
EP3536712
Grant Date:
May 31, 2023
Title:
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)
Oppositions:
1
Patent:
EP3645553
Grant Date:
Mar 15, 2023
Title:
Tropism-Modified Recombinant Viral Particles And Uses Thereof For The Targeted Introduction Of Genetic Material Into Human Cells
Oppositions:
2
Patent:
EP3695012
Grant Date:
Mar 8, 2023
Title:
Inhibition Of Hsd17B13 In The Treatment Of Liver Disease In Patients Expressing The Pnpla3 I148M Variation
Oppositions:
1
Patent:
EP2578688
Grant Date:
Feb 8, 2023
Title:
Adam6 Mice
Oppositions:
1

Competitors of Regeneron Pharmaceuticals, Inc.

KYMAB LIMITED

AMGEN INC.

DR. H. ULRICH DORRIES

Want to track Regeneron Pharmaceuticals, Inc.?

Feel free to send us a message here and we will get back to you